| Diffuse Large B-Cell Lymphoma
Columvi vs Epkinly
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Columvi vs Epkinly with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpkinly has a higher rate of injection site reactions vs Columvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epkinly but not Columvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Columvi
Epkinly
At A Glance
IV infusion
Every 3 weeks
CD20xCD3 bispecific T-cell engager
SC injection
Every 1-4 weeks
CD20xCD3 bispecific antibody
Indications
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
Dosing
Diffuse Large B-Cell Lymphoma Pretreat with obinutuzumab 1,000 mg IV on Cycle 1 Day 1; then administer COLUMVI IV: 2.5 mg step-up dose on Cycle 1 Day 8, 10 mg step-up dose on Cycle 1 Day 15, then 30 mg on Day 1 of Cycles 2-12 (21-day cycles; maximum 12 cycles or until disease progression or unacceptable toxicity).
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (monotherapy) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (+ lenalidomide and rituximab) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg monthly for Cycles 4-12 with lenalidomide 20 mg (Days 1-21) and rituximab 375 mg/m2 (Cycles 1-5); total 12 cycles or until progression.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Cytokine release syndrome, musculoskeletal pain, rash, fatigue
Serious Cytokine release syndrome, COVID-19 infection, sepsis, tumor flare
Most common (>=20%) CRS, fatigue, injection site reactions, musculoskeletal pain, pyrexia, abdominal pain, nausea, diarrhea, rash, upper respiratory tract infections, constipation, pneumonia, COVID-19, fever, cough, headache
Serious CRS, infections (sepsis, COVID-19, pneumonia, upper respiratory tract infections), pleural effusion, febrile neutropenia, fever, ICANS
Postmarketing Hemophagocytic Lymphohistiocytosis (HLH)
Pharmacology
Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager that binds CD20 on B cells and CD3 on T cells, causing T-cell activation and proliferation, cytokine secretion, and lysis of CD20-expressing B cells.
Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager (humanized IgG1) that simultaneously binds CD3 on T-cells and CD20 on lymphoma and healthy B-lineage cells, activating T-cells, inducing cytokine release, and causing B-cell lysis; in combination with rituximab it also mediates NK cell antibody-dependent cellular cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Columvi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Epkinly
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Columvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Epkinly
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Columvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Epkinly
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Genentech Patient FoundationCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGenmab Patient Assistance Program: Epkinly
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ColumviView full Columvi profile
EpkinlyView full Epkinly profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.